Skip to main content
. 2013 Dec;3(4):862–869. doi: 10.1086/674762

Table 1.

Baseline characteristics

Characteristic All subjects (n = 36) Survivors (n = 15) Nonsurvivors (n = 21)
Age at initiation, median (range), days 44. (1–359) 162 (1–359) 27. (1–321)
Length of follow-up, median (range), days NA 1,219.5 (585–4,283) NA
Ventilator use 36. (100) 15 (100) 21. (100)
ECMO use 11. (30.6) 4 (36) 7. (33.3)
Medications
 Nitric oxide 30. (83.3) 12 (80) 18. (85.7)
 Diuretics 25. (69.4) 9 (60) 16. (76.2)
 Dopamine 16. (44.4) 2 (13.3) 14. (66.7)
 Sildenafil 15. (41.7) 5 (33.3) 10. (47.6)
 Milrinone 6. (16.7) 2 (13.3) 4. (19.0)
 Dobutamine 1. (2.8) 0 (0) 1. (4.8)
Note

Data are no. (%), unless otherwise indicated. NA: not applicable; ECMO: extracorporeal membrane oxygenation.